Fig. 3

Prognostic value of single LIMK2 or PI4K2B gene in SCLC. A KM survival analysis of LIMK2 in George dataset (n = 77). SCLC patients were divided into low-expression (n = 13) and high-expression (n = 64) groups based on the optimal cut-off point. B KM survival analysis of PI4K2B in George dataset (n = 77). SCLC patients were divided into low-expression (n = 25) and high-expression (n = 52) groups based on the optimal cut-off point. C KM survival analysis of LIMK2 in GSE60052 dataset (n = 48). SCLC patients were divided into low-expression (n = 9) and high-expression (n = 39) groups based on the optimal cut-off point. D KM survival analysis of PI4K2B in GSE60052 dataset (n = 48). SCLC patients were divided into low-expression (n = 12) and high-expression (n = 36) groups based on the optimal cut-off point. E In GSE40275 dataset, boxplot of LIMK2 mRNA expression in SCLC tumors and normal tissues. F In GSE40275 dataset, boxplot of PI4K2B mRNA expression in SCLC tumors and normal tissues. G In GSE60052 dataset, boxplot of LIMK2 mRNA expression in SCLC tumors and normal tissues. H In GSE60052 dataset, boxplot of PI4K2B mRNA expression in SCLC tumors and normal tissues. I IHC detection of LIMK2 expression in two SCLC clinical specimens (T: Tumor, N: Normal tissue). J IHC detection of PI4K2B expression in two SCLC clinical specimens (T: Tumor, N: Normal tissue)